英夫利昔单抗联合肠内营养治疗克罗恩病的研究

Advances in the treatment of Crohn’s disease with Infliximab combined with enteral nutrition

克罗恩病(Crohn’s disease,CD)是一种可累及全消化道的病因不明的慢性炎性肉芽肿性疾病,其特点表现为易复发且难治愈。随着英夫利昔单抗在治疗CD上的广泛应用,其反应丧失等问题逐渐凸显,采取联合治疗成为目前的补救措施之一,目前已有临床研究表明,英夫利昔单抗联合肠内营养(enteral nutrition,EN)在治疗CD方面能有效诱导和维持CD缓解。本文就英夫利昔单抗联合EN治疗CD的作用机制、临床应用及不良反应等方面的研究作一概述。

Crohn’s disease(CD)is a chronic inflammatory granulomatous disease of unknown etiology that affects the entire digestive tract,characterized by recurrent and refractory symptoms.With the wide application of Infliximab in the treatment of CD,the problem of its loss of response gradually becomes prominent,and combination therapy has become one of the current remedial measures,there have been clinical studies showing that Infliximab combined with enteral nutrition(EN)can effectively induce and maintain remission in CD.In this paper,the mechanism,clinical application and adverse reactions of Infliximab combined with EN in the treatment of CD are reviewed.